Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia

British Journal of Haematology

Volumn 96, Issue 2, 1997, Pages 314-321

  Hiorns, Lynne R ^a,b   Swansbury, G John ^a   Mehta, Jayesh ^a   Min, Toon ^a   Dainton, Melissa G ^a   Treleaven, Jennie ^a   Powles, Raymond L ^a   Catovsky, Daniel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

APL; chromosome abnormalities; poor prognosis; t(15; 17)

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031040058     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.d01-2037.x     Document Type: Article

References (27)

1. Arthur D.C., Berger, R., Golomb, H.M., Swansbury, G.J., Reeves, B. R., Alimena, G., Van Den Berghe, H., Bloomfield, C.D., de la Chapelle, A., Dewald, G.W., Garson, O.M., Hagemeijer, A., Kaneko, Y., Mitelman, F., Pierre. R.V., Ruutu, T., Sakurai, M., Lawler, S.D. & Rowley, J.D. (1989) The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genetics and Cytogenetics, 40, 203-216.
2. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1976) Proposals for the classification of the acute leukaemias. British Journalof Haematology, 33, 451-458.
3. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1980) A variant form of hypergranular promyelocytic leukaemia (M3). British Journal of Haematology, 44, 169-170.
4. Berger, R., Le Conait, M., Derre, J., Vecchione, D. & Jonveaux, P. (1991) Cytogenetic studies in acute promyelocytic leukaemia: a survey of secondary chromosomal abnormalities. Genes, Chromosomes and Cancer, 3, 332-337.
5. Bloomfield, C.D., Lawrence, D., Arthur, D.C., Berg, D.T., Schiffer, C.A. & Mayer, R.J. (1994) Curative impact of intensification with highdose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood, 84, 111a.
6. Borrow, J., Goddard, A.D., Gibbons, B., Katz, F., Swirsky, D., Fioretos, T., Dube, I., Winfield, D.A., Kingston, J., Hagemeijer, A., Rees, J.K.H., Lister, T.A. & Solomon, E. (1992) Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. British Journal of Haematology, 82, 529-540.
7. Castaigne, S., Balitrand, N., De The, H., Dejean, A., Degos, L. & Chomienne, C. (1992) A PML/retinoic acid receptor α fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood, 79, 3110-3115.
8. Chen, Z., Brand, N.J., Chen, A., Chen, S.J., Tong, J.H., Wang, Z.Y., Waxman, S. & Zelent, A. (1993) Fusion between a novel kruppel-like zinc finger gene and the retinoic acid receptor-a locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO Journal, 12, 1161-1167.
9. Cox, D.R. (1972) Regression models and life tables. Journal of the Royal Statistical Society, 34, 187-202.
10. Dastugue, N., Payen, C., Larage-Pochitaloff, M., Bernard, P., Leroux, D., Huget-Rigal, F., Stoppa, A.M., Marit, G., Molina, L., Michallet, M., Maraninchi, D., Attal, M. & Reiffers, J., for the BGMT group (1995) Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia, 9, 1491-1498.
11. De La Chapelle, A., Knuutila, S., Elonen, E. & Vuopio, P. (1981) Chromosomal abnormalities in acute promyelocytic leukaemia. International Journal of Cancer, 27, 167-170.
12. De The, H., Chomienne, C., Lanotte, M., Degos, L. & Dejean, A. (1990) The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature, 347, 558-561.
13. Goddard, A.D., Borrow, J., Freemont, P.S. & Solomon, E. (1991) Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science, 254, 1371-1374.
14. Helenglass. G., Powles, R.L., McElwain, T.J., Lakhani, A., Milan, S., Gore, M., Nandi, A., Zuiable, A., Perren, T., Forgeson, G., Treleavan, J., Hamilton, C. & Millar, J. (1988) Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplantation, 3, 21-29.
15. Hiorns, L.R., Min, T., Swansbury, G.J., Zelent, A., Dyer, M.J.S. & Catovsky, D. (1994) Interstitial insertion of retinoic acid receptor-α gene in acute promyelocytic leukemia with normal chromosomes 15 and 17. Blood, 83, 2946-2951.
16. Hiorns, L.R., Swansbury, G.J. & Catovsky, D. (1995) An eight-way variant t(15;17) in acute promyelocytic leukemia elucidated using fluorescent in situ hybridization. Cancer Genetics and Cytogenetics, 83, 136-139.
17. Hogge, D.E., Misawa, S., Schiffer, C.A. & Testa, N. (1984) Promyelocytic blast crisis in chronic granulocytic leukemia with 15;17 translocation. Leukemia Research, 8, 1019-1023.
18. Keating, M.J., Cork, A., Broach, Y., Smith, T., Walters, R.S., McCredie, K.B., Trujillo, J. & Freireich, E.J. (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Research, 11, 119-133.
19. Larson, R.A., Kondo, K., Vardiman, J.W., Butler, A.E., Golomb, H.M. & Rowley, J.D. (1984) Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. American Journal of Medicine, 76, 827-841.
20. McKinney, C.D., Golden, W.L., Gemma, N.W., Swerdlow, S.H. & Williams, M.E. (1994) RARA and PML gene rearrangements in acute promyelocytic leukemia with complex translocations and atypical features. Genes, Chromosomes and Cancer, 9, 49-56.
21. Mehta, J., Powles, R., Singhal, S., Horton, C., Tait, D., Milan, S., Meller, S., Pinkerton, C.R. & Treleaven, J. (1995) Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplantation, 16, 499-506.
22. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. British Journal of Cancer, 35, 1-39.
23. Powles, R.L., Morgenstern, G.R., Kay, H.E.M., McElwain, T.J., Clink, H.M., Dady, P.J., Barrett, A., Jameson, B., Depledge, M.H., Watson, J.G., Sloane, J., Leigh, M., Lumley, H., Hedley, D., Lawler, S.D., Filshie, J. & Robinson, B. (1983) Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet, i, 612-615.
24. Redner, R.L., Rush, E.A., Faas, S., Rudert, W.A. & Corey, S.J. (1996) The t(5:17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 87, 882-886.
25. Swansbury, G.J., Lawler, S.D., Alimena, G., Arthur, D., Berger, R., Van den Burghe, H., Bloomfield, C.D., De la Chapelle, A., Dewald, G., Garson, O.M., Hagemeijer, A., Mitelman, F., Rowley, J.D. & Sakurai, M. (1994) Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genetics and Cytogenetics, 73, 1-7.
26. Tallman, M.S., Andersen, J., Schiffer, C.A., Applebaum, F.R., Feusner, J.E., Woods, W.G., Ogden, A., Weinstein, H., Shepherd, L., Rowe, J.M. & Wiernik, P.H. (1995) Phase III randomized study of all-transretinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia (APL). Blood, 86, 172a.
27. Wheatley, K., Burnett, A., Goldstone, A., Hann, I., Stevens, R., Rees, J. & Gray, R., on behalf of the MRC Adult and Childhood Leukaemia Working Parties (1995) A simple robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom Medical Research Council (MRC) AML 10 trial. Blood, 86, 598a.